Benzo(c)quinolizinium drugs inhibit degradation of ΔF508-CFTR cytoplasmic domain

Add time:09/30/2019    Source:infona.pl

Proteins comprising the first nucleotide-binding- and R-domains of wild-type and ΔF508 cystic fibrosis transmembrane conductance regulator (CFTR) have been synthesised by in vitro transcription/translation. The kinetics and extent of degradation of wild-type and ΔF508 cytoplasmic domain proteins in rabbit reticulocyte lysates, in which proteasome activity was inhibited, were similar, with a half-life of approximately 4h. The results show for the first time, that the benzo(c)quinolizinium compounds, MPB-07 and MPB-91, selectively inhibit degradation of the ΔF508 cytoplasmic domain protein. Studies using protease inhibitors demonstrated that both ΔF508 and wild-type proteins are substrates for cysteine proteases. The studies provide evidence that benzo(c)quinolizinium compounds protect a proteolytic cleavage site by direct binding to the first cytoplasmic domain of ΔF508-CFTR and this is a likely mechanism for increasing ΔF508-CFTR trafficking in intact cells.

We also recommend Trading Suppliers and Manufacturers of Benzo[c]quinolizinium (cas 231-40-3). Pls Click Website Link as below: cas 231-40-3 suppliers

Prev:Inhibition of ATP-sensitive K + channels by substituted benzo[c]quinolizinium CFTR activators
Next:Flow-injection chemiluminescence determination of aminoglycoside antibiotics using N-bromosuccinimide-FLUORESCEIN (cas 232-07-5) system)